Biologics manufacturing is coming into a brand new section the place agility and proximity matter as a lot as scale. For many years, the trade relied on the philosophy that “greater is best,” establishing huge, centralized services to drive down unit prices. Nonetheless, the bottom is shifting beneath our toes.
The increasing portfolio of biologic medicine dictates this shift. Over the previous 15 years, the variety of proteins coming into Part 1 scientific trials has doubled, and 50 p.c of latest biologics are uncommon or orphan medicinehighlighting the necessity for versatile manufacturing. We’re shifting away from a blockbuster-only world towards one outlined by fragmentation and precision. In the meantime, biomanufacturing infrastructure has grow to be more and more restricted.
To satisfy this accelerating demand for bioproducts, biotech innovators want high-quality, cost-effective approaches to manufacturing and improvements that allow small-volume manufacturing capability. Whereas conventional centralized services will proceed to play a significant position, early market and regulatory alerts level to a rising shift towards smaller, regional websites that may reply quicker to demand, provide disruption, and rising therapeutic wants.
The rising demand for personalised and rare-disease therapies necessitates a transition towards regulatory frameworks that assist distributed biomanufacturing via technological innovation. Present geopolitical instability underscores that distributed manufacturing is vital for sustaining each nation’s well being resilience and guaranteeing affected person entry.
Centralized manufacturing is displaying its limits
The “mega-factory” mannequin was constructed for a steady world, however stability is at present in brief provide. Ongoing provide chain disruptions and part shortages proceed to show weaknesses in single-site, globally dependent operations.
The impression on sufferers is measurable and alarming. Lengthy-standing, persistent shortages account for greater than 90% of all drug shortages in the USA, with the common length of present shortages now over 4 years.
Once we rely closely on centralization, scientific and business packages are more and more slowed as a result of important supplies, gear, or outsourced processes grow to be bottlenecks. As an illustration, delays in uncooked materials supply can push vital biologics shipments again by months, impacting affected person entry.
Massive services stay important for high-volume indications, however their dimension and complexity make speedy adaptation tough, forcing organizations to decide on between throughput and suppleness. It sometimes takes three to 5 years and over $200 million to construct typical biomanufacturing services. Most of these services are sometimes constructed for a single product kind and can’t quickly adapt to adjustments in product demand.
These pressures are forcing corporations to rethink whether or not centralization can meet the tempo and variety of recent biologics pipelines. Because the market demand for precision drugs, uncommon illness therapeutics, and small-batch biologics grow to be extra prevalent, centralized services alone could not suffice to satisfy various, pressing affected person wants.
The rise of versatile biomanufacturing
The answer to this rigidity lies within the adoption of intensified and steady processing. Advances in modular, closed, and automatic methods enable smaller services to function with consistency and decrease staffing necessities.
Steady manufacturing presents substantial advantagestogether with a diminished gear footprint of as much as 70%, a 3- to 5-fold improve in volumetric productiveness, enhanced product high quality consistency, and facility value reductions of 30–50% in comparison with conventional batch processes. These metrics make distributed manufacturing economically possible and operationally advantageous.
Importantly, world regulators are more and more accepting modular, single-use, and steady manufacturing methods for scientific and business provide, decreasing boundaries for regional deployment. We’re seeing revolutionary producers worldwide show that this strategy delivers high-quality therapeutics and is sweet enterprise.
For instance, in Q3 2025, WuXi Biologics introduced that its Eire facility was accepted by European Medicines Company (EMA) as a business manufacturing web site for a worldwide shopper’s biologic–one of many largest cell tradition processes utilizing single-use expertise worldwide. This web site deploys the WuXiUp platform for automated steady drug substance (DS) manufacturing at pilot-scale, demonstrating that single-use steady tech can meet rigorous regulatory requirements.
One other instance is Enzene Biosciences’ EnzeneX expertise, which was the primary fully-connected steady manufacturing (FCCM) strategy validated for business biologics provide. Enzene just lately (September 2025) inaugurated a brand new facility in Hopewell, New Jersey that may deploy the EnzeneX platform. This standardization between websites permits them to switch a course of from their R&D heart in Pune, India, to their New Jersey location with minimal friction, epitomizing the “copy-exact” mannequin needed for a distributed community.
Lastly, BiosanaPharma has deployed their “3C” course of — Steady, Closed, and Compact — to attain a large milestone by producing the primary monoclonal antibody (a biosimilar of omalizumab) manufactured with a completely steady course of to enter scientific trials in Australia. They’re now working to assist third eventstogether with biologic innovators and CDMOs, deploy the 3C platform to get improved effectivity from present services.
Conclusion: A turning level for biomanufacturing
Customized and highly-targeted therapeutics have gotten extra frequent, making native or regional manufacturing more and more useful for quicker affected person entry. This underscores how a hybrid community combining massive, centralized crops coupled with versatile regional websites will outline the following period of resilient biomanufacturing.
Biomanufacturing won’t grow to be decentralized instantly, however the tendencies are clear. Rising applied sciences, regulatory developments, and shifts in therapeutic demand are driving the trade towards a extra distributed strategy. Crucially, regulators and producers should associate to outline high quality threat administration requirements for distributed manufacturing — a significant step in securing world affected person entry to biologics.
Corporations that start making ready now by modernizing platforms, exploring modular facility designs, and pinpointing the place regional capability might strengthen resilience can be higher positioned to satisfy future wants. The following section of biologics manufacturing can be outlined by flexibility, proximity, and the power to ship therapies to sufferers extra rapidly.
Photograph: nevarpp, Getty Photos
Dr. Kerry Love is the co-founder and CEO of Sunflower Therapeuticsa women-owned and led biotechnology firm delivering next-generation protein manufacturing options that anybody can use to create revolutionary new medicines, vaccines, meals, and different bio-produced supplies. Kerry is an natural chemist by coaching, performing her doctoral research at MIT, and a biotech entrepreneur at coronary heart, having based two corporations and contributed to the beginning of many extra over the previous twenty years.
This publish seems via the MedCity Influencers program. Anybody can publish their perspective on enterprise and innovation in healthcare on MedCity Information via MedCity Influencers. Click on right here to learn the way.
